At GlioRay, we are at the forefront of a revolution in cancer treatment. Founded as a spin-out from the University of Southern Denmark (SDU) and the Technical University of Denmark (DTU), we are driven by a singular mission: to develop innovative, life-saving therapies for glioblastoma, one of the most aggressive and challenging forms of brain cancer.

Our Vision

Our vision is to transform the way glioblastoma is treated, offering patients new hope and extending lives through cutting-edge science. By harnessing the power of Auger radioligand therapy combined with advanced nanocarriers, we aim to target cancer cells with unprecedented precision, minimizing damage to surrounding healthy tissue and maximizing therapeutic outcomes.

Our Technology

GlioRay's proprietary technology integrates the latest advancements in nanocarriers and Auger radioligand therapy. Our unique approach involves designing nano-scale carriers that deliver radioactive isotopes directly to cancer cells using convection-enhanced delivery. This delivery system increases the efficacy of the treatment while reducing side effects, offering a more effective and patient-friendly solution.

Our Roots

Our journey began in the research labs of SDU and DTU, where a team of dedicated scientists came together with a shared passion for making a difference in the fight against glioblastoma. With strong academic foundations and a commitment to rigorous research, we have transformed groundbreaking ideas into a promising therapeutic platform.

Our Team

Our multidisciplinary team brings together expertise in oncology, nanotechnology, radiopharmaceuticals, and neurosurgery. Together, we are united by a common goal: to push the boundaries of what is possible in cancer treatment. Our collaborative spirit and innovative mindset drive us forward as we work to bring our groundbreaking therapies from the lab to the clinic.

Join us on our journey to change the face of cancer treatment. Together, we can light the way to a brighter future.